tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

FATE Stock Latest News

Fate Therapeutics presents updated Phase 1 data of FT819
The FlyFate Therapeutics presents updated Phase 1 data of FT819
2M ago
FATE
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
PremiumCompany Announcements
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
3M ago
FATE
Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks
PremiumCompany Announcements
Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks
3M ago
FATE
Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment
PremiumRatings
Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment
3M ago
FATE
Fate Therapeutics reports Q3 EPS (27c), consensus (28c)
PremiumThe Fly
Fate Therapeutics reports Q3 EPS (27c), consensus (28c)
3M ago
FATE
Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
PremiumThe FlyFate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
3M ago
FATE
Is FATE a Buy, Before Earnings?
Premium
Pre-Earnings
Is FATE a Buy, Before Earnings?
4M ago
FATE
Fate Therapeutics Advances CAR T-Cell Therapy with New Clinical Study
Premium
Company Announcements
Fate Therapeutics Advances CAR T-Cell Therapy with New Clinical Study
4M ago
FATE
Fate Therapeutics’ Phase 1 Study: A Potential Game-Changer in Autoimmune Disease Treatment
PremiumCompany Announcements
Fate Therapeutics’ Phase 1 Study: A Potential Game-Changer in Autoimmune Disease Treatment
4M ago
FATE
Fate Therapeutics’ Innovative CAR T-Cell Therapy Study: A Potential Game-Changer in Cancer Treatment
PremiumCompany Announcements
Fate Therapeutics’ Innovative CAR T-Cell Therapy Study: A Potential Game-Changer in Cancer Treatment
4M ago
FATE
Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7
PremiumThe Fly
Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7
4M ago
FATE
Fate Therapeutics Reports Promising Phase 1 Trial Results
PremiumCompany Announcements
Fate Therapeutics Reports Promising Phase 1 Trial Results
4M ago
8K
FATE
Fate Therapeutics upgraded to Outperform from Neutral at Wedbush
PremiumThe FlyFate Therapeutics upgraded to Outperform from Neutral at Wedbush
4M ago
FATE
Hold Rating Maintained for Fate Therapeutics’ FT819 Amid Efficacy and Durability Concerns
Premium
Ratings
Hold Rating Maintained for Fate Therapeutics’ FT819 Amid Efficacy and Durability Concerns
4M ago
FATE
Fate Therapeutics Appoints New CFO Kamal Adawi
Premium
Company Announcements
Fate Therapeutics Appoints New CFO Kamal Adawi
4M ago
8K
FATE
Fate Therapeutics appoints Adawi as CFO
PremiumThe Fly
Fate Therapeutics appoints Adawi as CFO
4M ago
FATE
Fate Therapeutics Faces Nasdaq Delisting Risk: Implications for Investors
PremiumCompany Announcements
Fate Therapeutics Faces Nasdaq Delisting Risk: Implications for Investors
6M ago
FATE
Fate Therapeutics Reports Q2 2025 Financial Results
PremiumCompany Announcements
Fate Therapeutics Reports Q2 2025 Financial Results
6M ago
FATE
Fate Therapeutics price target lowered to $2.50 from $4 at Wells Fargo
PremiumThe Fly
Fate Therapeutics price target lowered to $2.50 from $4 at Wells Fargo
6M ago
FATE
Cautious Hold Rating for Fate Therapeutics Amid Developmental and Regulatory Uncertainties
PremiumRatingsCautious Hold Rating for Fate Therapeutics Amid Developmental and Regulatory Uncertainties
6M ago
FATE
Cautious Hold Rating on Fate Therapeutics Amid Promising CAR-iT Developments and Early Stage Trials
Premium
Ratings
Cautious Hold Rating on Fate Therapeutics Amid Promising CAR-iT Developments and Early Stage Trials
6M ago
FATE
Fate Therapeutics Announces Corporate Restructuring Plan
Premium
Company Announcements
Fate Therapeutics Announces Corporate Restructuring Plan
6M ago
8K
FATE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >